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的是 H-2 和 H-3，对 Raji 细胞的 IC50 分别为 15µg/mL 和 7.8µg/mL，具有抗氧化
活性的是 H-2、CB-4 和 CB-6，对 DPPH 的清除率的 IC50 分别是 61.2µg/mL、
15.8µg/mL 和 200µg/mL。CB-4 和 CB-6 有微弱的抗金黄色葡萄球菌活性，MIC










































































Marine fungus has become an important source of bioactive natural product, 
recently. Today there are about 300 new compounds derived from marine fungi. 
Because of its unique living environment, marine fungus has produced special 
metabolites with unusual chemical structure to adapt the living condition such as 
salinity, high pressure and low temperature. For these reasons, the metabolites from 
marine fungus may possess new bioactivities or novel chemical structures. 
Secondary metabolites from two marine fungi strains were observed in this study. 
The entire region ITS1-5.8s-ITS2 of CB -2 was amplified by PCR. Associated with 
morphological character, CB-2 was identified as Articulospora sp.. Employing 
different isolation and purification methods, six compounds were isolated from the 
fermentation broth of CB-2, two of them were methyl 4,6–Dihydroxy- 
2,3-dimethybenzoate (CB-4) and 3-(4-hydroxy-benzyl)-piperazine-2,5-dione (CB-6). 
Four compound were isolated from HLY-2, they were 7–Hydroxy-4, 6–dimethyl-3H– 
isobenzofuran-1-one (H-2), 7-Methoxy-4,6-dimethyl-3H-isobenzofunan-1-one (H–3), 
nectriapyron (H-4), ergosterol (H-6). 
Four of above compounds were studied for their bioactivities, including 
antimicrobial, anti-tumor, and antioxidant activities. H-2 and H-3 showed anti-tumor 
activity against Raji cell line with the IC50 value as 15µg/mL and 7.8µg/mL 
respectively. H-2, CB-4, and CB-6 showed anti-oxidant activity as scavenging of 
DPPH radicals with the IC50 value as 61.2µg/mL, 15.8µg/mL and 200µg/mL 
respectively. CB-4 and CB-6 showed moderate activity against S. aurens with the IC50 
100µg/mL respectively. H-2 and CB-6 showed moderate activity against Penicillium 















  Production of anti-tumor agent mycoepoxydiene was optimized by orthogonal 
design. Two types of fermentation were tested, which are agar surface and submerged 
fermentation. The result shows that the optimal condition for mycoepoxydiene 
production included potato 250g/L, sea water 300ml/L, glucose 30g/L, lactose 50g/L, 
KH2PO4 0.65mmol/L, (NH4)2SO4 1g/L in the agar surface condition. The production 
of mycoepoxydiene reached 521mg/L, and it equaled to 16 times of the production in 
customary half-seawater PD medium. The differences of production, biomass, and 
consuming rate of sugar, amino acid, and phosphate between agar surface and 
submerged fermentation were studied. 
Strain HLY-2 was fermented by optimal medium in agar surface manner for 10L, 
and 1.5g mycoepoxydiene were gained. The in vivo test showed that the compound 
has the toxicity to mouse with LD50 125.98mg/kg, and the anti-tumor activity 
inhibited mice sarcoma s-180 cell line with ED50 11.87mg/kg. The therapy index was 
10.61. MycoE also suppressed human gastric cancer BGC-823 xenograft on nude mice，the 
inhibition rate was 42.62% at the dose of 10mg/kg which equals to 1/12 of LD50, and the mice 
body weight of that group had the biggest increase. 
Primary anti-tumor mechanism of mycoepoxydiene was also studied. The results 
of morphological observation, FCM, comet assay, and DNA ladder electrophoresis 
showed that the compound did not induce apoptosis of tumor cell. The exact 
mechanism of its anti-tumor activity, maybe necrosis or something else, is still 
puzzled. It is needed to have further study. 
Our study indicated that metabolites from strain CB-2 and HLY-2 were worth to 
be researched in-depth. Compound mycoepoxydiene had the potentiality to be a new 
anti-tumor drug in clinic. 
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早的成功实例。此后，从海绵中发现了抗病毒药物 ara-A。上世纪 60 年代发现
了河豚毒素并确定了其化学结构，相继完成了河豚毒素的人工合成。1969 年
Spriggins 从加勒比海的柳珊瑚 Plexaura homomalla 中分离获得前列腺素 15R－
PGA2。上述这些重要发现极大地刺激了科学家对海洋生物次生代谢产物研究的
兴趣[1]。 
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在随后的几十年，放线菌成了药物开发的焦点，但是，随着 1976 年环孢菌





















海洋真菌的产生的化合物，比如 sargassamide、halimide 和 avrainvillamide
都表现出了选择性的肿瘤细胞抑制活性，在体内实验中具有抑制 P-388 淋巴白
血病的活性。更重要的是，这些化合物每一个都具有独一无二的特征，如，
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产物。第一类包含有氯倍半烯萜，chloriolins A, B和C[3]，与革盖菌素B和二氢革 
盖菌素 C 相近，尽管化合物 chloriolins 在由NC I进行的以疾病为导向的活性筛 
表 1 来自海洋真菌的生物活性物质 
Tab.1 Bioactive compounds from marine fungi 
Metabolite(s) Source Class of compound Activity  Ref. 
Phomopsidin Phomopsis sp. (obtained 
from a submerged 
mangrove branch) 
 Showed an IC50 value of 









from the surface of the 







showed a mean IC50 of 
1.1 µg /mL in the 
National Cancer 









OUPS-4 isolated from the 





The potency of the 
leptosins against a P388 
leukemia cell line ranged 









(isolated from the sponge 
Niphates olemda) 
Anthraquinone Showed activity against 
S. aureus, Escherichia 
coli and B. subtilis  
[37] 






activity against  
S. aureus (10 μg/mL), M. 
luteus (20μg/mL), 
Corynebacterium xerosis 




Microsphaeropsin Microsphaeropsis sp 
(derived from 





against Ustilago violacea 
and Mycotypha 
microspora at 50 lg level 
[41] 











MIC values starting at 2 
lg/ml 
[42] 
Ulocladol Ulocladium botrytis 
obtained from sponge 



















选中没有活性，但是革盖菌素 B对人乳腺癌 T-47D 细胞和中枢神经系统肿肿瘤
SNB -75有细胞毒活性[4]。从 Bahamas 岛附近的红树林栖息地的一个漂浮木样上
分离到的海洋真菌 CNC-477 以海水为基质进行发酵后，得到两类化合物，
Neomangicols A-C 和 Mangicols A-G。Neomangicols A-C 具有未报道过的 C 骨
架结构，其中 Neomangicols A 对人乳腺癌细胞株 MCF-7 和人结肠癌细胞株 
CACO-2 的 IC50分别为 4.9μM 和 5.7μM，Neomangicols B 对该细胞株的 IC50 
为27μM[20-21]。Sansalvamide是从一株海洋真菌中发现的一个新化合物，见图1，
美国国家癌症研究所（NCI）测定了其对 60 种细胞株的细胞毒活性，平均 IC50
为 27.4μg/mL，其对结肠癌细胞株 COLO205 和黑色素瘤细胞株 SK-MEL-2 的
IC50 分别为 3.5 和 5.9ng/mL，这一数据比 FDA 核准的一些抗肿瘤剂表现出的
细胞毒活性还要高[22]。中山大学的林永成组从南中国海红树林真菌＃732 的发酵
液中分离得到的新化合物 Enniatin G 具有抗肝癌 Heps7402 的活性，ED50为
12μg/mL[24]。同组李厚金博士从红树植物内生真菌＃2509 中分离得到了一个新
的化合物 Ergosta-8(9), 22-diee-3,5,6,7-tetrol(3β, 5α, 6β, 7α, 22Z)，其对正常人肝细
胞株 L-02 的 IC50 为 13.621μg/mL，对人肝癌细胞株 Bel-7402和人大细胞肺癌
细胞株 NCI14460 的 IC50 分别为 8.445μg/mL 和 5.03 μg/mL。这种选择性的细
胞毒性具有很高的研究价值[25]。Michio 等从浸没的木质样品中分离得到的一株
海洋真菌 Myrothecium roridum 能产生一种新的杆孢菌素，12, 13-deoxyroridin 
E，该化合物对 HL-60 和L1210 细胞株的 IC50 分别 为 25 和 15ng/mL[27]。从
Pohnpei 的珊瑚礁采集到的一个红树植物浸没枝条样品，分离到的一种茎点霉
（Phomopsis sp.），发酵液分离得到的化合物 Phomopsidin 可以抑制微管集合，
IC50 为5.7μM，并对其生物合成途径及抗微管聚合活性机理进行了深入的研究。 
由海洋真菌产生的抗细菌化合物也呈上升的趋势。Pestalone，见图 2，是从
海洋真菌 Pestalotia sp. 分离到的一种氯苯甲酮类化合物，对耐甲氧西林的金黄
色葡萄球菌的 MIC 为 37ng/mL，对耐万古霉素的粪肠球菌的 MIC 为 78ng/mL，
具备进一步研究开发成为抗感染药的实力。有趣的是，这种化合物只有在与单细
胞的海洋细菌 CNJ-328 共培养的时候才能产生，有可能这个抗生素是为了与细菌
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Aspergillus tamarii 中分离到的一个新五元环羟吲哚生物碱，是环匹克尼酸类化
合物，其对 Mycrococcus luteus 的 MIC 为 16.7μg/mL[9]。Zopfiellamide A 是


































A, R=Cl; B, R=Br  












Neomangicols Cb                      Phonopsidinc 
图 1 来自海洋真菌的抗肿瘤化合物结构 
Fig.1 Chemical structure of compound isolated from marine-derived fungi 
showing antitumor properties 
资料来源：a：Gilbert N belofsky, Paul R Jensen, William Fenical. Sansalvamede: A new cytotoxic cyclic 
depsipeptide produced by a marine fungus of genus Fusarium [J]. Tetrahedron Letters,1999, 40: 2913 -2916. b：
Matthew K Renner, Paul R Jensen, William Fenical. Mangicols: structure and biosynthesis of a new class of 
sesterterpene polyols from a marine fungus of the genus Fusarium[J]. J. Org. Chem,2000, 65: 4843-4852. c：
Kobayashi H, Meguro S, Yoshimoto T, Namikoshi M. Absolute structure, biosynthesis, and anti-microtubule 
activity of phomopsidin, isolated from a marine-derived fugus Phomopsis sp. [J]. Tetrahedron, 2003, 59; 455-459. 
 
氏阳性菌 Bacillus brevis, Bacillus subtilis, B. licheniformis, Corynebacterium 
insidiosum, Micrococcus luteus, Mycobacteriumphlei, Arthrobacter citreus 以及链霉
菌和革兰氏阴性菌醋酸钙不动杆菌，对这些菌的 MIC 在 2-10μg/mL 之间[10]。分
离自海草的海洋真菌 Kirschsteiniothelia maritima 能发酵产生一种芳香醛类的化
合物，ascochital，见图 2，其对枯草芽孢杆菌的 MIC 为 500ng/mL[46]。Modiolides 
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